Skip to main content

Table 2 Association between MD significant loci and breast cancer risk (overall, ER-positive, and ER-negative)

From: Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci

Region

rsID

CHR

Position1

Allele2

MD phenotype

Overall breast cancer4

ER-positive breast cancer4

ER-negative breast cancer4

Z-score

p Value

Beta

SE3

p Value

Beta

SE

p Value

Beta

SE

p Value

DA

1q21.2

rs11205303

1

149,906,413

T/C

 − 6.772

1.25 E−11

0.050

0.006

1.05 E−14

0.057

0.008

8.25 E−14

0.040

0.012

6.67 E−04

2q14.2

rs17625845

2

121,089,731

T/C

7.949

1.87 E−15

 − 0.046

0.008

1.73 E−08

 − 0.032

0.010

8.94 E−04

 − 0.114

0.015

1.13 E−13

4q13.3

rs6851733

4

75,518,708

T/C

6.874

6.23 E−12

0.009

0.008

2.20 E−01

0.001

0.009

9.58 E−01

0.018

0.014

1.97 E−01

5q11.2

rs150249911

5

52,119,132

A/G

 − 5.928

3.06 E−09

0.038

0.027

1.49 E−01

0.048

0.032

1.33 E−01

0.053

0.050

2.87 E−01

5q23.2

rs335189

5

122,446,856

C/G

6.655

2.84 E−11

0.027

0.007

8.38 E−05

0.026

0.008

1.46 E−03

0.012

0.012

3.32 E−01

5q35.1

rs2042239

5

169,566,329

A/G

6.485

8.87 E−09

0.028

0.006

9.80 E−06

0.037

0.008

1.02 E−06

0.003

0.012

7.72 E−01

6q25.1

rs9397436

6

151,952,002

A/G

7.951

1.86 E−15

0.184

0.012

2.00 E−54

0.138

0.014

1.71 E−22

0.272

0.021

4.01 E−40

7p11.2

rs10155920

7

55,308,930

T/C

5.755

8.66 E−09

0.011

0.008

2.01 E−01

0.012

0.010

2.50 E−01

 − 0.001

0.015

9.35 E−01

8q24.13

rs58847541

8

124,610,166

A/G

5.994

2.05 E−09

 − 0.063

0.009

4.33 E−13

 − 0.055

0.010

1.17 E−07

 − 0.077

0.016

1.00 E−06

10q21.2

rs10995187

10

64,273,026

A/G

8.933

4.14 E−19

0.129

0.009

2.85 E−49

0.134

0.011

1.74 E−37

0.092

0.016

8.18 E−09

11p15.5

rs4980383

11

1,902,097

T/C

 − 7.228

4.90 E−13

 − 0.076

0.006

4.36 E−34

 − 0.083

0.007

6.20 E−29

 − 0.051

0.011

8.31 E−06

12p12.1

rs11836164

12

26,446,625

T/C

6.028

1.66 E−09

 − 0.013

0.007

6.81 E−02

 − 0.003

0.009

7.32 E−01

 − 0.025

0.013

5.78 E−02

12p11.2

rs7297051

12

28,174,817

T/C

6.166

7.01 E−10

0.120

0.007

1.73 E−60

0.110

0.009

3.49 E−36

0.140

0.014

6.45 E−25

12q23.2

rs833472

12

103,005,100

T/C

7.134

9.76 E−13

0.078

0.020

7.59 E−05

0.085

0.024

3.04 E−04

0.049

0.037

1.80 E−01

19q13.33

rs1231281

19

49,239,200

A/G

6.860

6.87 E−12

 − 0.008

0.006

2.30 E−01

 − 0.010

0.008

2.07 E−01

 − 0.002

0.012

8.72 E−01

20q13.13

rs17789629

20

48,892,374

A/C

 − 5.478

4.30 E−08

 − 0.011

0.008

1.32 E−01

 − 0.001

0.009

9.48 E−01

 − 0.034

0.014

1.44 E−02

22q13.1

rs34066050

22

38,612,604

A/G

 − 5.534

3.14 E−08

 − 0.034

0.006

5.58 E−08

 − 0.042

0.008

2.35 E−08

 − 0.010

0.011

3.78 E−01

22q13.2

rs6001939

22

40,892,794

T/C

8.791

1.48 E−18

 − 0.117

0.010

1.31 E−32

 − 0.106

0.012

1.20 E−19

 − 0.115

0.018

8.77 E−11

NDA

1p12

rs78395856

1

119,495,096

A/C

5.525

3.29 E−08

 − 0.037

0.018

3.46 E−02

 − 0.044

0.021

3.31 E−02

 − 0.037

0.031

2.35 E−01

5q14.1

rs413472

5

80,930,992

T/C

5.551

2.84 E−08

0.004

0.006

5.49 E−01

0.010

0.008

2.11 E−01

 − 0.012

0.012

3.18 E−01

8p11.23

rs16885613

8

36,848,357

T/C

 − 12.788

1.92 E−37

 − 0.076

0.008

1.58 E−20

 − 0.070

0.010

5.06 E−13

 − 0.099

0.015

2.38 E−11

10q21.2

rs2138555

10

64,220,494

A/G

5.900

3.63 E−09

 − 0.044

0.006

1.48 E−12

 − 0.047

0.008

3.89 E−10

 − 0.030

0.011

8.58 E−03

12q22

rs61938093

12

96,026,737

T/C

 − 6.266

3.72 E−10

0.089

0.007

1.34 E−38

0.091

0.008

5.53 E−28

0.069

0.013

3.39 E−08

22q13.2

rs73169097

22

41,027,870

T/C

6.012

1.83 E−09

 − 0.120

0.010

1.98 E−34

 − 0.110

0.012

5.34 E−21

 − 0.117

0.018

4.33 E−11

PMD

1q21.2

rs1868992

1

149,908,108

A/G

5.517

3.44 E−08

 − 0.027

0.007

1.64 E−04

 − 0.029

0.008

7.09 E−04

 − 0.030

0.013

1.98 E−02

5q23.2

rs335189

5

122,446,856

C/G

6.196

5.78 E−10

0.027

0.007

8.38 E−05

0.026

0.008

1.46 E−03

0.012

0.012

3.32 E−01

5q31.1

rs76876329

5

131,237,759

T/C

5.530

3.21 E−08

0.012

0.009

1.87 E−01

0.007

0.011

5.11 E−01

0.014

0.017

3.99 E−01

5q33.3

rs11745230

5

158,171,008

T/G

 − 5.793

6.90 E−09

 − 0.064

0.008

1.30 E−14

 − 0.065

0.010

3.47 E−11

 − 0.068

0.015

6.72 E−06

5q35.1

rs2112670

5

169,557,594

A/G

 − 5.598

2.17 E−08

 − 0.013

0.006

4.71 E−02

 − 0.023

0.008

2.83 E−03

0.012

0.012

3.03 E−01

6p22.3

rs3819405

6

16,399,557

T/C

5.806

6.42 E−09

0.040

0.007

1.25 E−08

0.045

0.008

5.38 E−08

0.027

0.013

3.45 E−02

6q25.1

rs4897107

6

149,601,591

T/C

6.842

7.81 E−12

0.036

0.008

5.98 E−06

0.049

0.010

3.55 E−07

0.018

0.015

2.15 E−01

6q25.1

rs9397436

6

151,952,002

A/G

7.303

2.81 E−13

0.184

0.012

2.00 E−54

0.138

0.014

1.71 E−22

0.272

0.021

4.01 E−40

8p11.23

rs10087804

8

36,858,140

C/G

6.282

3.35 E−10

 − 0.077

0.008

8.34 E−21

 − 0.071

0.010

3.64 E−13

 − 0.098

0.015

6.55 E−11

10q21.2

rs10995187

10

64,273,026

A/G

10.424

1.92 E−25

0.129

0.009

2.85 E−49

0.134

0.011

1.74 E−37

0.092

0.016

8.18 E−09

11p15.5

rs4980383

11

1,902,097

T/C

 − 5.860

4.62 E−09

 − 0.076

0.006

4.36 E−34

 − 0.083

0.007

6.20 E−29

 − 0.051

0.011

8.31 E−06

12q23.2

rs61941038

12

102,989,316

A/T

 − 6.477

9.37 E−11

 − 0.075

0.020

1.47 E−04

 − 0.085

0.024

3.07 E−04

 − 0.032

0.037

3.86 E−01

15q26.1

rs4499190

15

94,275,057

G/C

 − 5.654

1.57 E−08

 − 0.001

0.007

8.90 E−01

0.001

0.009

8.71 E−01

 − 0.008

0.013

5.69 E−01

16q12.2

rs11646715

16

53,824,007

A/G

7.183

6.84 E−13

0.046

0.006

6.89 E−13

0.042

0.008

4.14 E−08

0.055

0.012

1.60 E−06

19q13.33

rs12462111

19

49,171,306

T/C

5.847

5.02 E−09

 − 0.017

0.007

1.03 E−02

 − 0.015

0.008

5.32 E−02

 − 0.011

0.012

3.51 E−01

  1. 1Genomic positions based on build GRCh37/hg19
  2. 2Coded as reference allele/effect allele
  3. 3Standard error
  4. 4Beta estimates, SEs, and p values of overall, ER-positive, and ER-negative breast cancer were based on the GWAS results published by the Breast Cancer Association Consortium (BCAC)